Literature DB >> 12076758

Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.

Kathleen M Tatti1, Brent E Korba, Heather L Stang, Simon Peek, John L Gerin, Bud C Tennant, Raymond F Schinazi.   

Abstract

During more than 104 weeks of treatment with lamivudine (3TC) in chronic woodchuck hepatitis virus (WHV) carrier woodchucks, viral recrudescence occurred. Analysis of WHV DNA polymerase from woodchuck serum samples by PCR followed by DNA sequencing demonstrated that all samples were wild type at the conserved YMDD motif in domain C. Four of the six 3TC-treated woodchucks showed a mixture of the wild-type Ala (GCT) and the mutant Thr (ACT) at the conserved amino acid residue 566 (FLLA) in domain B of the WHV polymerase region. The appearance of the A566T mutation was temporally associated with viral recrudescence. This change is analogous with the amino acid 181 (FLLA) in HBV where 3TC selects for a change from Ala to Thr in humans. In the woodchuck, the Ala to Thr change in the polymerase gene results in a mutation of the WHV surface protein (amino acid 377) from Trp (TGG) to an opal codon (TGA), which may prematurely terminates the polypeptide. Three WHV molecular infectious clones were constructed to study this mutation in greater detail in vitro: A566T, analogous to A181T in HBV; M589V, analogous to the M204V in HBV; and the double mutant A566T/M589V, analogous to A181T/M204V in HBV. These mutants exhibited drug-sensitivity and replication profiles that paralleled those reported for analogous HBV variants. In transfected Huh7 cells, WHV containing the M589V mutation conferred at least 100-fold increased resistance to 3TC, but replicated approximately 5-fold less efficiently than wild-type virus as judged by both extracellular virus production and intracellular DNA replicative forms. In contrast, A566T mutant was approximately 10-fold more resistant to 3TC, replicated intracellularly as well as wild type, but produced 10-fold lower levels of virions than wild type. These findings are consistent with the observation that the A566T mutation alters the overlapping WHV surface antigen reading frame. WHV carrying mutations in the conserved YMDD motif, while not directly selected during lamivudine therapy in WHV carrier woodchucks, are replication competent in cell culture indicating the potential for their emergence in treated animals. These results further illustrate the utility of the WHV/woodchuck model to studies of HBV-drug resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076758     DOI: 10.1016/s0166-3542(02)00019-0

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.

Authors:  Hiromi Yatsuji; Chiemi Noguchi; Nobuhiko Hiraga; Nami Mori; Masataka Tsuge; Michio Imamura; Shoichi Takahashi; Eiji Iwao; Yoshifumi Fujimoto; Hidenori Ochi; Hiromi Abe; Toshiro Maekawa; Chise Tateno; Katsutoshi Yoshizato; Fumitaka Suzuki; Hiromitsu Kumada; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

Review 3.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

4.  Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.

Authors:  Stephan Menne; Scott D Butler; Andrea L George; Ilia A Tochkov; Yuao Zhu; Shelly Xiong; John L Gerin; Paul J Cote; Bud C Tennant
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

5.  Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations.

Authors:  Jeong Han Kim; Young Kul Jung; Moon Kyung Joo; Ji Hoon Kim; Hyung Joon Yim; Jong-Jae Park; Jae Seon Kim; Young-Tae Bak; Jong Eun Yeon; Kwan Soo Byun
Journal:  J Korean Med Sci       Date:  2009-01-19       Impact factor: 2.153

6.  Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.

Authors:  Radhakrishnan P Iyer; Yi Jin; Arlene Roland; John D Morrey; Samir Mounir; Brent Korba
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

7.  Hepatitis B virus gene mutations in liver diseases: a report from New Delhi.

Authors:  Abdul Malik; Deepak Kumar Singhal; Abdulmajeed Albanyan; Syed Akhtar Husain; P Kar
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

8.  Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.

Authors:  Ann W Walsh; David R Langley; Richard J Colonno; Daniel J Tenney
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.